Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Automation, miniaturization, and new software algorithms are improving throughput and accuracy.

Accelerating Discovery and Development with Advances in High-Throughput Screening

Insights into molecular behaviors and predictive capabilities are bringing numerous benefits.

Molecular Modeling in Formulation Development

Platform processes and effective risk assessments help overcome time and cost challenges.

Considering Process Scaling for Monoclonal Antibodies During Early Phase Development

Feliza Mirasol is the science editor for 

Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition. 

Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation

With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.

Regeneron Forms R&D Cell Therapy Unit from 2seventy bio Platform Acquisition

The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.

Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone

Under the collaboration, Orionis will receive $47 million upfront to leverage its Allo-Glue platform to discover small-molecule monovalent glues.

Genentech Partners with Orionis Biosciences to Discover and Develop Molecular Glue Class Medicines

According to a press release, the implications go to the extent that within the next 10 years, more than 50% of approved drugs will involve AI in their development and/or manufacturing.

CPHI Annual Report Predicts AI Transformation of All Drug Development Processes by 2026

HitGen has entered into a research service agreement with Nested Therapeutics for use of HitGen’s DNA-encoded library for drug discovery.